Latest Ratios: P/E Ratio 2.6x · EV/EBITDA 4.0x · ROE 9.9%. (2004–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.3B | $2.2B | $1.8B | $2.7B | $2.9B | $3.6B | $6.4B | $11.9B | $4.8B | $4.6B | $2.9B |
| Enterprise Value | $2.2B | $2.1B | — | — | $2.4B | $1.4B | $4.3B | $10.1B | $3.5B | $3.5B | $2.0B |
| P/E Ratio → | 2.58 | 6.71 | 24.55 | 12.66 | — | — | — | 79.55 | — | — | 56.31 |
| P/S Ratio | 2.21 | 1.94 | 6.60 | 11.17 | 12.09 | 7.45 | 13.47 | 14.27 | 16.55 | 36.50 | 22.65 |
| P/B Ratio | 0.64 | 0.67 | — | — | 1.15 | 1.37 | 2.41 | 4.14 | 3.94 | 4.58 | 3.87 |
| P/FCF | — | — | — | — | — | — | — | 3.34 | — | — | 12.50 |
| P/OCF | — | — | — | — | — | — | — | 3.31 | — | — | 12.25 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.86 | — | — | 10.07 | 2.90 | 9.07 | 12.07 | 12.08 | 27.45 | 15.13 |
| EV / EBITDA | 3.98 | 3.72 | — | — | — | — | — | 26.93 | — | — | — |
| EV / EBIT | 3.92 | 6.84 | — | — | — | — | — | 27.34 | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | 2.82 | — | — | 8.35 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.3% | 97.3% | 87.4% | 100.0% | 100.0% | 99.7% | -9.5% | 49.7% | -11.8% | -71.9% | -7.8% |
| Operating Margin | 45.1% | 45.1% | -68.3% | -36.8% | -54.3% | -34.2% | -37.4% | 44.2% | -15.5% | -70.7% | -8.9% |
| Net Profit Margin | 28.8% | 28.8% | 26.9% | 88.3% | -90.4% | -25.9% | -63.9% | 17.9% | -10.1% | -91.0% | 41.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 9.9% | 9.9% | — | — | -8.4% | -4.7% | -11.0% | 7.3% | -2.6% | -13.1% | 9.6% |
| ROA | 9.4% | 9.4% | — | — | -4.4% | -2.3% | -5.2% | 4.0% | -2.1% | -9.8% | 7.1% |
| ROIC | 11.8% | 11.8% | — | — | -7.9% | -24.8% | -16.7% | 57.4% | — | — | — |
| ROCE | 15.4% | 15.4% | — | — | -3.0% | -3.4% | -3.4% | 11.0% | -3.8% | -8.6% | -1.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | — | — | 0.01 | 0.01 | 0.01 | 0.01 | — | 0.00 | 0.00 |
| Debt / EBITDA | 0.01 | 0.01 | — | — | — | — | — | 0.07 | — | — | — |
| Net Debt / Equity | — | -0.03 | — | — | -0.19 | -0.83 | -0.79 | -0.64 | -1.06 | -1.14 | -1.28 |
| Net Debt / EBITDA | -0.15 | -0.15 | — | — | — | — | — | -4.91 | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | -0.51 | — | — | -4.15 |
| Interest Coverage | 136.71 | 136.71 | -2.39 | 4.18 | -6.74 | -10.54 | -15.42 | 199.92 | -39.28 | -122.40 | -244.47 |
Net cash position: cash ($88M) exceeds total debt ($7M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 20.15 | 20.15 | — | — | 8.11 | 8.58 | 8.45 | 10.26 | 6.04 | 6.98 | 9.70 |
| Quick Ratio | 20.00 | 20.00 | — | — | 8.01 | 8.55 | 8.45 | 10.26 | 6.04 | 6.97 | 9.70 |
| Cash Ratio | 19.61 | 19.61 | — | — | 7.83 | 8.30 | 8.12 | 10.11 | 5.87 | 6.70 | 9.38 |
| Asset Turnover | — | 0.33 | — | — | 0.05 | 0.09 | 0.08 | 0.14 | 0.20 | 0.10 | 0.12 |
| Inventory Turnover | 1.32 | 1.32 | — | — | 0.59 | 0.08 | 1475.12 | 1647.41 | 1169.84 | 783.16 | 465.25 |
| Days Sales Outstanding | — | 17.46 | — | — | 117.02 | 96.81 | 132.39 | 35.02 | 42.38 | 120.02 | 66.16 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 38.8% | 14.9% | 4.1% | 7.9% | — | — | — | 1.3% | — | — | 1.8% |
| FCF Yield | — | — | — | — | — | — | — | 30.0% | — | — | 8.0% |
| Buyback Yield | 0.0% | 0.0% | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $66M | $66M | $66M | $66M | $66M | $65M | $58M | $52M | $49M | $46M |
Includes 30+ ratios · 22 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LKFT stock.
Lakefront Biotherapeutics N.V.'s current P/E ratio is 2.6x. The historical average is 32.8x.
Lakefront Biotherapeutics N.V.'s current EV/EBITDA is 4.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 15.3x.
Lakefront Biotherapeutics N.V.'s return on equity (ROE) is 9.9%. The historical average is -8.4%.
Based on historical data, Lakefront Biotherapeutics N.V. is trading at a P/E of 2.6x. Compare with industry peers and growth rates for a complete picture.
Lakefront Biotherapeutics N.V. has 97.3% gross margin and 45.1% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Lakefront Biotherapeutics N.V.'s Debt/EBITDA ratio is 0.0x, indicating low leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
Unsustainable profit-driven deleveraging
Low Multiples Reflect One-Time Earnings
Based on reported figures, LKFT trades at a P/E of 2.58 and EV/EBITDA of 3.98, multiples that appear depressed against Incyte's 60.00 P/E and 26.65 EV/EBITDA and may be inflated in their apparent cheapness by a single quarter's earnings.
The 2.58 trailing P/E is computed on earnings dominated by the $782.1M net income in 2025Q4, a figure that appears non-recurring given operating losses in adjacent quarters. Against a P/B of 0.64, the market appears to be pricing the equity near its book value, which suggests skepticism toward the durability of reported earnings rather than a clear value signal. Investors should monitor whether trailing multiples remain low once the 2025Q4 gain is excluded, since the current figures warrant further investigation before being treated as evidence of undervaluation.
Margins Swing on Lumpy Revenue
Gross margin in LKFT's reported figures ranged from -185.8% in 2026Q2 to 99.9% in 2025Q4, while operating margin reached -87.3% in 2025Q2, indicating earnings power that does not behave like a stable operating business.
The dispersion in gross margin suggests cost of revenue does not scale with the revenue line, so a single quarter's margin tells little about structural economics. Operating margin of -5.4% in 2026Q3 against R&D burden implies research spending continues to outrun the revenue base, based on reported figures. Net margin appears to be driven by non-operating items, as the 86.8% figure in 2025Q4 diverges sharply from operating results, so operating margin is the more reliable gauge of earning power here.
Returns Spike Without Compounding Base
As reported in the filings, ROIC was -1.0% in 2026Q3 and -1.5% in 2026Q1, with a single 20.5% reading in 2025Q4 that appears to reflect the one-time gain rather than durable capital productivity.
The 2025Q4 ROIC and ROE spike of 20.5% and 27.5% sits against negative ROIC in every other reported quarter with data, so it does not indicate a compounding trend. Returns are better described as episodic than as evidence of a durable capital base. Investors should monitor whether returns remain positive once the non-recurring gain is removed from the calculation.
Current Ratio Masks Thin Cash Cushion
Based on LKFT's reported figures, the current ratio of 46.49 in 2026Q3 looks exceptionally strong, yet cash of $96.3M against quarterly operating outflows of roughly $33M to $83M implies a short runway relative to burn.
A current ratio this elevated is less informative than the absolute cash balance, which appears thin against recurring operating cash losses. Quick ratio of 46.39 is nearly identical, suggesting current assets are dominated by cash and receivables rather than inventory, which means liquidity depends heavily on continued access to the existing balance. Under severe stress, the position may not hold if operating outflows persist at recent levels, though this warrants further investigation given limited disclosure.
Misapplied Ratio: Current Ratio
The current ratio is most commonly misapplied to a pre-revenue biotech like LKFT, where it can show extreme comfort while cash burn quietly erodes the runway that the ratio fails to capture.
A current ratio of 46.49 appears to signal strength, but it obscures that liquidity is measured against a balance sheet whose current assets may not convert to cash fast enough to fund quarterly operating outflows. Free cash flow runway, measured as cash divided by average quarterly burn, is a more relevant metric for assessing survival time. Investors should monitor that figure, since the present ratio does not reveal how quickly the cash base is being consumed.